Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-08-25 16:25:06 ET · period of report 2026-08-24 · accession 0000907654-26-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-25 16:25 | 2026-08-24 | ORKA | Edwards Larry Todd | Chief Commercial Off | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
| D | 2026-08-25 16:25 | 2026-08-24 | ORKA | Edwards Larry Todd | Chief Commercial Off | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-24 | A | A | 100,000 | $0.00 | 100,000 | D | — | — | (F1) The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-08-24 | A | A | 20,000 | $0.00 | 20,000 | D | $102.42 · — to 2036-08-23 | 20,000 Common Stock | (F2) The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter. |